Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 3/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041175 | 0.83 | S1PR1 (0.46) | SLC6A2SLC6A4SLC6A3F10PRSS1 | |
| SCHEMBL3436382 | 0.83 | S1PR1 (0.46) | SLC6A2SLC6A4SLC6A3F10PRSS1 | |
| SCHEMBL4757240 | 0.78 | CHRM2 (0.45) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4011897 | 0.75 | RORC (0.44) | SLC6A2SLC6A4SLC6A3F10PRSS1 | |
| SCHEMBL10839544 | 0.73 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1896746 | 0.72 | USP30 (0.51) | — | |
| SCHEMBL13214492 | 0.71 | MEN1 (0.45) | GAA | |
| SCHEMBL3436380 | 0.71 | DRD4 (0.52) | — | |
| SCHEMBL8686279 | 0.70 | MEN1 (0.52) | TSHR | |
| SCHEMBL3736399 | 0.70 | RORC (0.49) | SLC6A2SLC6A4SLC6A3F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | SLC6A2 2876/4885SLC6A4 2509/4885SLC6A3 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.